Wells Fargo
NWBO

Wells Fargo’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Wells Fargo’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-21,550
Closed -$11K – 6737
2016
Q3 		$11K Buy
21,550
+17,000
+374% +$7.77K ﹤0.01% 5747
2016
Q2 		$2K Sell
4,550
-14,945
-77% -$16K ﹤0.01% 5984
2016
Q1 		$28K Buy
19,495
+3,730
+24% +$7.36K ﹤0.01% 5421
2015
Q4 		$50K Sell
15,765
-56
-0.4% -$269 ﹤0.01% 5284
2015
Q3 		$99K Sell
15,821
-2,126
-12% -$19.9K ﹤0.01% 4891
2015
Q2 		$179K Buy
17,947
+11,185
+165% +$98K ﹤0.01% 4676
2015
Q1 		$49K Sell
6,762
-686
-9% -$4.62K ﹤0.01% 5019
2014
Q4 		$40K Buy
7,448
+4,014
+117% +$20.5K ﹤0.01% 5104
2014
Q3 		$17K Sell
3,434
-13,644
-80% -$83.8K ﹤0.01% 5392
2014
Q2 		$114K Sell
17,078
-9,641
-36% -$61.4K ﹤0.01% 4628
2014
Q1 		$194K Buy
26,719
+25,219
+1,681% +$149K ﹤0.01% 4350
2013
Q4 		$6K Buy
+1,500
New +$5.8K ﹤0.01% 5341

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Wells Fargo's NWBO Position: Q4 2016 in Review

Wells Fargo sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 21,550 shares — an estimated $11K sold.

Wells Fargo first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $194K in Q1 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Wells Fargo reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Wells Fargo sold 21,550 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $11K.
  • Wells Fargo first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
  • Wells Fargo's Northwest Biotherapeutics, Inc. Common stock position peaked at $194K in Q1 2014.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.